 Sunitinib is a chemotherapy approved by the FDA as a standard of care treatment for renal cell carcinoma RCC. Fatigue is a very common side effect of sunitinib that frequently causes dose reductions. The cause of this fatigue remains unclear. This study will use a special type of scan to study sunitinib-induced fatigue in relation to exercise. 